A
A. Azzedine
Publications - 5
Citations - 735
A. Azzedine is an academic researcher. The author has contributed to research in topics: FOLFIRI & Irinotecan. The author has an hindex of 5, co-authored 5 publications receiving 650 citations.
Papers
More filters
Journal ArticleDOI
Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000–01 FFCD/SFRO study
Bruno Chauffert,F. Mornex,Franck Bonnetain,Ph. Rougier,Christophe Mariette,O. Bouche,J.-F. Bosset,Thomas Aparicio,Laurent Mineur,A. Azzedine,Pascal Hammel,J. Butel,N. Stremsdoerfer,Philippe Maingon,Laurent Bedenne +14 more
TL;DR: This intensive induction schedule of CHRT was more toxic and less effective than gemcitabine alone and was confirmed in a per-protocol analysis for patients who received 75% or more of the planned dose of radiotherapy.
Journal ArticleDOI
Randomized phase III trial in elderly patients comparing LV5FU2 with or without irinotecan for first-line treatment of metastatic colorectal cancer (FFCD 2001–02)
Thomas Aparicio,Sandrine Lavau-Denes,Jean-Marc Phelip,Emilie Maillard,Jean-Louis Jouve,D. Gargot,Mohamed Gasmi,Christophe Locher,X. Adhoute,Pierre Michel,Faiza Khemissa,Thierry Lecomte,J. Provençal,Gilles Breysacher,Jean-Louis Legoux,Céline Lepère,J. Charneau,J. Cretin,L. Chone,A. Azzedine,O. Bouche,Iradj Sobhani,Laurent Bedenne,Emmanuel Mitry,P. Amoyal,D. Auby,Jean-Baptiste Bachet,M. Baconnier,R. Benoit,O. Berthelet,Anne Thirot Bidault,C. Bineau,G. Bordes,Nadia Bouarioua,Eveline Boucher,O. Boulat,D. Cleau,P. Couzigou,E. Cuillerier,I. Cumin,B. Denis,F. Di Fiore,V. Derias,J. Ezenfis,Roger Faroux,A. Gagnaire,G. Gatineau-Sailliant,B. Garcia,Dominique Genet,A. Gueye,Pascal Hammel,J.P. Lagasse,B. Landi,Côme Lepage,C. Lobry,Catherine Lombard-Bohas,May Mabro,R. Mackiewicz,J. Martin,X. Moncoucy,François Morvan,M. Mozer,M. Pauwels,F. Petit-Laurent,P. Pouderoux,P. Prost,A.M. Queuniet,Mohamed Ramdani,C. Rebischung,Ph. Rougier,Matthieu Schnee,Jean-François Seitz,L. Stefani,Julien Taieb,Eric Terrebonne,Patrick Texereau,J. Thaury,David Tougeron,Achim Weber,F. Ricard,F. Bonnetain,F. Masskouri,C. Choine,F. Guiliani,G. Le Pessec,H. Fattouh,N. Le Provost,C. Girault,M. Schneider +88 more
TL;DR: In this elderly population, adding irinotecan to an infusional 5-FU-based CT did not significantly increase either PFS or OS, and Classic LV5FU2 was associated with an improved OS compared with simplified LV 5FU2.
Journal ArticleDOI
Overweight is associated to a better prognosis in metastatic colorectal cancer: A pooled analysis of FFCD trials.
Thomas Aparicio,Michel Ducreux,Roger Faroux,Emilie Barbier,Sylvain Manfredi,Thierry Lecomte,Pierre-Luc Etienne,Laurent Bedenne,Jaafar Bennouna,Jean-Marc Phelip,Eric Francois,Pierre Michel,Jean-Louis Legoux,Mohamed Gasmi,Gilles Breysacher,Philippe Rougier,Aimery de Gramont,Côme Lepage,Olivier Bouché,Jean-François Seitz,Antoine Adenis,A. Alessio,A. Aouakli,A. Azzedine,A. Bedjaoui,Anne Thirot Bidault,A. Blanchi,A. Botton,A. Cadier-Lagnes,A. Fatisse,A. Gagnaire,A. Gilbert,A. Gueye,A. Hollebecque,A. Lemaire,Abakar Mahamat,A. Marre,A. Patenotte,A. Rotenberg,A. Roussel,Anne Thirot-Bidault,A. Votte,Achim Weber,A. Zaanan,A.C. Dupont-Gossart,Anne-Laure Villing,A.M. Queuniet,Bruno Coudert,Bernard Denis,B. Garcia,B. Lafforgue,B. Landi,B. Leduc,Benjamin Linot,Bernard Paillot,B. Rhein,B. Winkfield,C. Barberis,C. Becht,Clément Belletier,C. Berger,C. Bineau,Christian Borel,C. Brezault,C. Buffet,C. Cornila,C. Couffon,C. de la Fouchardiere,C. Giraud,Cedric Lecaille,C. Lepere,C. Lobry,Clara Locher,C. Lombard-Bohas,C. Paoletti,C. Platini,C. Rebischung,Corinne Sarda,C. Vilain,C. Briac-Levaché,Dominique Auby,D. Baudet-Klepping,D. Bechade,D. Besson,Denis Cléau,D. Festin,Dany Gargot,Dominique Genet,D. Goldfain,D. Luet,David Malka,Denis Péré-Vergé,D. Pillon,D. Sevin-Robiche,D. Smith,D. Soubrane,David Tougeron,D. Zylberait,E. Carola,E. Cuillerier,E. Dorval Danquechin,E. Echinard,E. Janssen,Emilie Maillard,Emmanuel Mitry,E. Norguet-Monnereau,Etienne Suc,Eric Terrebonne,E. Zrihen,E.A. Pariente,F. Almaric,Franck Audemar,F. Bonnetain,Françoise Desseigne,F. Dewaele,F. Di Fiore,François Ghiringhelli,F. Husseini,Faiza Khemissa,F. Kikolski,François Morvan,F. Petit-Laurent,F. Riot,F. Subtil,F. Zerouala-Boussaha,François-Xavier Caroli-Bosc,G. Boilleau-Jolimoy,G. Bordes,Gerard Cavaglione,G. Coulanjon,Gael Deplanque,G. Gatineau-Saillant,Gael Goujon,G. Medinger,G. Roquin,H. Brixi-Benmansour,H. Castanie,Herve Lacroix,H. Maechel,Hervé Perrier,H. Salloum,Hélène Senellart,I. Baumgaertner,Isabelle Cumin,I. Graber,Isabelle Trouilloud,J. Boutin,J. Butel,J. Charneau,J. Cretin,Jérôme Dauba,J. Deguiral,J. Egreteau,J. Ezenfis,J. Forestier,J. Goineau,J. Lacourt,J. Lafon,J. Martin,J. Meunier,Jessika Moreau,Jocelyne Provencal,Julien Taieb,J. Thaury,J. Tuaillon,Julien Vergniol,J. Villand,Julie Vincent,Julien Volet,J-B. Bachet,J.C. Barbare,J.C. Souquet,J.D. Grangé,J.F. Dor,Jean Francois Paitel,Jean-Louis Jouve,Jean-Luc Raoul,J.M. Cheula,J.-M. Gornet,J.M. Sabate,J.M. Vantelon,J.N. Vaillant,J.P. Aucouturier,J.P. Barbieux,J.P. Herr,J.P. Lafargue,J.P. Lagasse,J.P. Latrive,J.P. Plachot,J.P. Ramain,J.P. Robin,Jean-Philippe Spano,J.-Y. Douillard,K. Beerblock,Karine Bouhier-Leporrier,K. Slimane Fawzi,Laurent Cany,Laurence Chone,Laetitia Dahan,L. Gasnault,L. Rob,L. Stefani,L. Wander,M. Baconnier,M. Ben Abdelghani,M. Benchalal,M. Blasquez,M. Carreiro,M. Charbit,Martin Combe,M. Duluc,M. Fayolle,M. Gignoux,M Giovannini,M. Glikmanas,May Mabro,M. Mignot,M. Mornet,Mireille Mousseau,M. Mozer,M. Pauwels,M. Pelletier,Marc Porneuf,Mohamed Ramdani,Matthieu Schnee,M. Tissot,M. Zawadi,M.-C. Clavero-Fabri,M.C. Gouttebel,Marie-Christine Kaminsky,M.P. Galais,N. Abdelli,N. Barrière,N. Bouaria,Nadia Bouarioua,N. Delas,N. Gérardin,N. Hess-Laurens,N. Stremsdoerfer,O. Berthelet,O. Boulat,Olivier Capitain,O. Favre,P. Amoyal,P. Bergerault,Pascal Burtin,P. Cassan,P. Chatrenet,P. Chiappa,P. Claudé,P. Couzigou,P. Feydy,P. Follana,P. Geoffroy,P. Godeau,Pascal Hammel,P. Laplaige,P. Lehair,P. Martin,P. Novello,P. Pantioni,P. Pienkowski,P. Pouderoux,P. Prost,Philippe Ruszniewski,P. Souillac,Patrick Texereau,Thévenet P,P.A. Haineaux,R. Benoit,Romain Coriat,R. Lamy,R. Mackiewicz,S. Beorchia,S. Chaussade,Sandrine Hiret,S. Jacquot,S. Lavau Denes,S. Montembault,S. Nahon,S. Nasca,S. Nguyen,S. Oddou-Lagraniere,S. Pesque-Penaud,S. Fratte,T. Chatellier,Touraj Mansourbakht,T. Morin,Thomas Walter,Valérie Boige,Vincent Bourgeois,V. Derias,Veronique Guerin-Meyer,Vincent Hautefeuille,V. Jestin Le Tallec,Veronique Lorgis,V. Quentin,V. Sebbagh,V. Veuillez,Xavier Adhoute,X. Coulaud,Yves Becouarn,Y. Coscas,Y. Courouble,Y. Le Bricquir,Y. Molin,Y. Rinaldi,Y.H. Lam,Z. Ladhib +308 more
TL;DR: Overweight patients had a prolonged OS compared with normal weight patients with mCRC, and the association of overweight with better OS was only observed in men.
Journal ArticleDOI
Cancer du pancréas localement évolué non resécable : chimioradiothérapie d’induction suivie de chimiothérapie par gemcitabine contre chimiothérapie exclusive par gemcitabine : résultats définitifs de l’étude de phase III 2000–2001de la FFCD et de la SFRO
M. Barhoumi,F. Mornex,F. Bonnetain,F. Bonnetain,Ph. Rougier,C. Mariette,O. Bouche,J.-F. Bosset,Thomas Aparicio,L. Mineur,A. Azzedine,P. Hammel,J. Butel,N. Stremsdoerfer,P. Maingon,Laurent Bedenne,Laurent Bedenne,Bruno Chauffert,Bruno Chauffert +18 more
TL;DR: Ce schema d’induction intensive par chimioradiotherapie concomitante est plus toxique et moins efficace que la gemcitabine seule.
Journal ArticleDOI
Prognostic factors in patients treated with second-line chemotherapy for advanced gastric cancer: results from the randomized prospective phase III FFCD-0307 trial
Yann Touchefeu,Rosine Guimbaud,C. Louvet,Laetitia Dahan,Emmanuelle Samalin,Emilie Barbier,K. Le Malicot,Romain Cohen,J.-M. Gornet,Thomas Aparicio,S. Nguyen,A. Azzedine,Pierre-Luc Etienne,J.M. Phelip,Pascal Hammel,N. Chapelle,David Sefrioui,Laurent Mineur,Côme Lepage,Olivier Bouché +19 more
TL;DR: Prognostic factors in L2 for progression-free survival (PFS) and overall survival (OS) were analyzed using a Cox model and age ≥ 60 years at diagnosis and ECOG score 0/1 before L2 were the only favorable prognostic factors for OS.